AB2 Bio Ltd.
3 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency As Open Label Extension (NCT03512314) | AB2 Bio Ltd. | 2018-01-24 |
| Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency (NCT03113760) | AB2 Bio Ltd. | 2017-07-21 |
| Therapeutic Use of Tadekinig Alfa in Adult-onset Still's Disease (NCT02398435) | AB2 Bio Ltd. | 2015-02-01 |
Track AB2 Bio Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.